Clinical trials
Chronic Hepatitis B Infection clinical trials
Below are recruiting chronic hepatitis b infection clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05492565Enrolling by invitation
Follow-up study for people on HIV prevention pills
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
Seville, AndalusiaAges 18 years+ - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Miami Beach, FloridaAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75 - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
La Jolla, CaliforniaAges 18–75 - NCT05189925RecruitingPhase 1
Correcting a missing immune enzyme using an mRNA cell therapy
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
Bethesda, MarylandAges 18–75 - NCT07708116RecruitingPhase 1
First human trial of CTX-187 for healthy people and those with chronic infection
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
GroningenAges 18–65 - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT07203755RecruitingPhase 1
Combination vaccine for whooping cough, Hib, and meningitis
This trial tests a new combination vaccine that protects against whooping cough, Haemophilus influenzae type b (a cause of meningitis and pneumonia), and several types of meningococcal disease (a cause of meningitis and bloodstream infections). It may help reduce the number of shots needed for children.
Shangqiu, HenanAges 2 months–6 years - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT05304234RecruitingPhase 2
Testing ways to detect liver cancer risk in Native patients
This Phase 2 study focuses on people at higher risk for liver cancer due to liver scarring or chronic hepatitis B. It may help improve screening and outcomes for American Indian and Alaska Native people who could benefit from closer monitoring.
Tahlequah, OklahomaAges 18–75 - NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Guangzhou, GuangdongAges 20–40 - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07189377RecruitingPhase 4
Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Toronto, OntarioAges 18 years+ - NCT07227441Recruiting
Chronic Infections and Inflammation in ME/CFS
This study looks at how chronic infections and inflammation affect people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) compared to healthy people. Researchers want to understand what causes symptoms and find better ways to help.
San Francisco, CaliforniaAges 18 years+ - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b infection?
- Yes. Clin2 currently lists 161 recruiting chronic hepatitis b infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.